Skip to main content

Migraine: diagnosis and management

Buy Article:

$51.00 plus tax (Refund Policy)



Migraine is the most common form of disabling primary headache and affects approximately 12% of studied Caucasian populations. Non-pharmacological management of migraine largely consists of lifestyle advice to help sufferers avoid situations in which attacks will be triggered. Preventive treatments for migraine should usually be considered on the basis of attack frequency, particularly its trend to change with time, and tract­ability to acute care. Acute care treatments for migraine can be divided into non-specific treatments (general anal­gesics, such as aspirin or non-steroidal anti-­inflammatory drugs) and treatments relatively specific to migraine (ergotamine and the triptans). The triptans − sumatriptan, naratriptan, rizatriptan, zolmitriptan, almotriptan, eletriptan and frovatriptan − are potent serotonin, 5-HT1B/1D, receptor agonists which represent a major advance in the treatment of acute migraine. Chronic daily headache in association with analgesic overuse is probably the major avoidable cause of headache disability in the developed world. (Intern Med J 2003; 33: 436−442)

Keywords: brainstem; headache; serotonin agonist; treatment

Document Type: Original Article


Affiliations: Institute of Neurology, The National Hospital for Neurology and Neurosurgery, London, United Kingdom

Publication date: September 1, 2003

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Partial Open Access Content
Partial Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more